niacinamide has been researched along with dasatinib in 37 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (24.32) | 29.6817 |
2010's | 25 (67.57) | 24.3611 |
2020's | 3 (8.11) | 2.80 |
Authors | Studies |
---|---|
Curtiss, FR | 1 |
von Mehren, M | 1 |
Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; D'Adamo, D; DeMatteo, RP; Guo, T; Hom, G; Maki, RG; Schwartz, GK; Singer, S; Veach, D; Wong, GC | 1 |
Thomas, X | 1 |
Faivre, S; Le Tourneau, C; Raymond, E | 1 |
Dykens, JA; Hirakawa, B; Hynes, J; Jamieson, J; Jessen, BA; Marroquin, LD; Nadanaciva, S; Patyna, S; Will, Y | 1 |
Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N | 1 |
Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
Geoerger, B; Leblond, P | 1 |
Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
Corey, SJ; Park, BJ; Whichard, ZL | 1 |
Celeghini, C; Melloni, E; Norcio, A; Secchiero, P; Voltan, R; Zauli, G | 1 |
Claasen, J; Frenzel, LP; Gehrke, I; Hallek, M; Krause, G; Kuckertz, M; Patz, M; Veldurthy, A; Wendtner, CM | 1 |
Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S | 1 |
Chang, AY; Wang, M | 1 |
Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D | 1 |
Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
Robert, C; Sibaud, V | 1 |
Beijnen, JH; de Vries, N; Schinkel, AH; Sparidans, RW; Tang, SC; Wagenaar, E | 1 |
Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y | 1 |
Ding, JF; Zhong, DF | 1 |
Fan, L; Han, TT; Li, JY; Xu, W | 1 |
Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B | 1 |
Galanis, A; Levis, M | 1 |
de Bont, ES; den Dunnen, WF; Hoving, EW; Kampen, KR; Lourens, HJ; Meeuwsen-de Boer, TG; Scherpen, FJ; Sie, M; Zomerman, WW | 1 |
Bose, SK; Di Bisceglie, AM; Kwon, YC; Meyer, K; Ray, R; Ray, RB; Steele, R | 1 |
Ha, AS; Imran, TF; Joseph, J; Shah, R; Thomas, R | 1 |
Brossart, P; Diehl, L; Garbi, N; Gevensleben, H; Grünwald, B; Heine, A; Held, SA; Höchst, B; Knolle, P; Krüger, A; Kurts, C; Schilling, J | 1 |
Biancheri, P; Foster, MR; Fyfe, MC; MacDonald, TT; Rowley, A; Sirohi, S; Solanke, Y; Walshe, CA; Webber, S; Wood, E | 1 |
Berellini, G; Bitter, H; Branford, S; Buonamici, S; Cowan-Jacob, SW; Dodd, S; Donovan, J; Furet, P; Hassan, AQ; Hofmann, F; Hughes, TP; Iyer, V; Jahnke, W; Keen, NJ; Lombardo, F; Loo, A; Marzinzik, AL; Palmer, M; Pelle, X; Petruzzelli, L; Ross, DM; Schoepfer, J; Sellers, WR; Thohan, S; Vanasse, KG; Warmuth, M; Wylie, AA; Zhu, W | 1 |
Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I | 1 |
Fujimoto, E; Horio, D; Ishigaki, H; Kanemura, S; Kijima, T; Kitai, H; Koda, Y; Kuribayashi, K; Mikami, K; Minami, T; Morimura, O; Nakajima, Y; Negi, Y; Niki, M; Shibata, E; Takahashi, R; Yokoi, T | 1 |
Friedman, R; G Lindström, HJ | 1 |
Gao, H; Qiu, Y; Rao, Y; Sun, X; Sun, Y; Weng, Q; Yang, Y | 1 |
Amiri, W; Friedman, R; Lindahl, E; Oruganti, B; Rahimullah, R; Yang, J | 1 |
10 review(s) available for niacinamide and dasatinib
Article | Year |
---|---|
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2007 |
New developments in multitargeted therapy for patients with solid tumours.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2008 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles | 2012 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
27 other study(ies) available for niacinamide and dasatinib
Article | Year |
---|---|
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib; Thiazoles | 2007 |
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Topics: Adenosine Triphosphate; Animals; Benzamides; Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Electron Transport; Galactose; Glucose; Imatinib Mesylate; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Thiazoles | 2008 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles | 2008 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Epothilones; Female; Humans; Morpholines; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Pyrimidines; Signal Transduction; Sirolimus; Sorafenib; Tamoxifen; Thiazoles | 2012 |
MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Dasatinib; Down-Regulation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrimidines; Sorafenib; Thiazoles | 2012 |
Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
Topics: Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Humans; Lethal Dose 50; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Thiazoles; Treatment Outcome; Tumor Cells, Cultured | 2012 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Dasatinib; DNA, Complementary; Female; Gene Dosage; Half-Life; Indoles; Male; Maternal-Fetal Exchange; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA; Sex Characteristics; Sorafenib; Sunitinib; Thiazoles | 2013 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles | 2014 |
Inhibition of c-Kit by tyrosine kinase inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles | 2015 |
Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
Topics: Apoptosis; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Ependymoma; Extracellular Signal-Regulated MAP Kinases; Humans; Intercellular Signaling Peptides and Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Signal Transduction; Sorafenib | 2015 |
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cyclic S-Oxides; Dasatinib; Epithelial-Mesenchymal Transition; Female; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imatinib Mesylate; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; RNA, Messenger; Sorafenib; Spheroids, Cellular; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Cells, Cultured | 2015 |
Heart failure associated with small molecule tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Dasatinib; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2016 |
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Topics: Celecoxib; Cell Differentiation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Immune Tolerance; Indoles; Monocytes; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2016 |
Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis.
Topics: Benzamides; Biopsy; Colitis, Ulcerative; Cytokines; Dasatinib; HT29 Cells; Humans; Interleukin-8; Leukocytes, Mononuclear; Macrophages; Mitogen-Activated Protein Kinase 14; Myofibroblasts; Naphthalenes; Niacinamide; Primary Cell Culture; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; src-Family Kinases; Syk Kinase | 2016 |
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Topics: Allosteric Regulation; Allosteric Site; Animals; Catalytic Domain; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Niacinamide; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays | 2017 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib | 2017 |
EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle Checkpoints; Cell Proliferation; Dasatinib; Drug Screening Assays, Antitumor; Ephrin-A2; Humans; Lung Neoplasms; Niacinamide; Receptor, EphA2; Small Cell Lung Carcinoma; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cell Line, Tumor; Computer Simulation; Dasatinib; Drug Discovery; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Niacinamide; Pyrazoles | 2020 |
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
Topics: Antineoplastic Agents; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imidazoles; Models, Molecular; Niacinamide; Proteolysis; Pyrazoles; Pyridazines | 2020 |
Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Niacinamide; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |